{
    "clinical_study": {
        "@rank": "55577", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the role of magnesium deficiency in the pathogenesis of decreased serum\n      vitamin D and reduced bone density in children with chronic cholestatic liver disease."
        }, 
        "brief_title": "Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease", 
        "condition": [
            "Alagille Syndrome", 
            "Cholestasis", 
            "Biliary Atresia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Biliary Atresia", 
                "Cholestasis", 
                "Alagille Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Patients receive magnesium sulfate IV over 1 hour on day 3.  Patients then receive oral\n      magnesium gluconate supplementation daily.  Treatment with magnesium sulfate repeats once at\n      3-6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of liver disease with chronic cholestasis Nonsyndromic intrahepatic\n             cholestasis Alagille's syndrome Extrahepatic biliary atresia\n\n          -  Direct bilirubin greater than 2 mg/dL OR Bile acids greater than 20 micromoles/L\n\n          -  No hepatic decompensation defined as one or more of the following: Ascites Peripheral\n             edema PT at least 4 seconds longer than control Albumin less than 3 g/dL\n\n        --Patient Characteristics--\n\n          -  Renal: No significant renal disease\n\n          -  Cardiovascular: No significant cardiovascular disease\n\n          -  Pulmonary: No significant pulmonary disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "December 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00007033", 
            "org_study_id": "199/15488", 
            "secondary_id": "CHMC-C-91-3-7"
        }, 
        "intervention": [
            {
                "intervention_name": "magnesium gluconate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "magnesium sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Magnesium Sulfate"
        }, 
        "keyword": [
            "Alagille syndrome", 
            "biliary atresia", 
            "cholestasis", 
            "gastrointestinal disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "January 21, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45229-3039"
                }, 
                "name": "Children's Hospital Medical Center - Cincinnati"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Children's Hospital Medical Center, Cincinnati", 
            "last_name": "James Heubi", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00007033"
        }, 
        "results_reference": {
            "PMID": "12183720", 
            "citation": "Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R Jr, Couser R, Rhodes P. Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J Pediatr. 2002 Aug;141(2):237-42."
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Hospital Medical Center, Cincinnati", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2002"
    }, 
    "geocoordinates": {
        "Children's Hospital Medical Center - Cincinnati": "39.103 -84.512"
    }
}